About Repligen Corporation This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and unce ...

WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2024. Repligen Corporation is a global life sciences company that develops and commercial ...

Company Overview - Repligen (RGEN) shares increased by 4.4% to $125.32 in the last trading session, following a significant volume of shares traded, contrasting with a 24.4% loss over the past four weeks [1] - The company announced the promotion of Olivier Loeillot to president and CEO, effective September 1, 2024, which may have contributed to the recent share price increase [1] Earnings Expectations - Repligen is expected to report quarterly earnings of $0.33 per share, reflecting a year-over-year decline of 37.7% [2] - Revenue projections for the upcoming quarter are $154.32 million, down 3.1% compared to the same quarter last year [2] Stock Performance and Trends - The consensus EPS estimate for Repligen has remained unchanged over the last 30 days, indicating a lack of upward momentum in earnings estimate revisions [3] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] - In the same industry, AnaptysBio, Inc. (ANAB) also holds a Zacks Rank of 3 (Hold) and saw a 4.9% increase in its last trading session [3][4]

Repligen Corporation (RGEN) announced that it has promoted Olivier Loeillot, its current chief commercial officer (CCO), as its new president and chief executive officer (CEO), effective from Sep 1, 2024. The company's current CEO, Tony J. Hunt, will step down from his role and will transition to executive chair with effect from Sep 1, 2024. Shares of RGEN fell 11.9% on Jun 13 following the announcement of the news. Olivier Loeillot joined Repligen as president and CCO in October last year. Prior to joining ...

WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors ("Board") has approved the planned transition of Tony J. Hunt from Chief Executive Officer ("CEO") to Executive Chair, effective September 1, 2024. The Company's Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. L ...

Leadership Transition - Repligen Corporation announced the transition of Tony J. Hunt from CEO to Executive Chair, effective September 1, 2024, with Olivier Loeillot appointed as the new CEO [6] - The Board of Directors believes that this leadership succession plan will ensure the company's ongoing success and strategic vision [1][6] - Olivier Loeillot has nearly 30 years of industry experience, previously serving as Bioprocess President at Cytiva, overseeing a multi-billion dollar bioprocess portfolio [1][2] Company Performance - Under Tony Hunt's leadership, Repligen's revenue grew from approximately $63 million in 2014 to $639 million in 2023, reflecting an average annual growth rate of over 30% [2] - The company has achieved innovation leadership in bioprocessing through disciplined acquisitions, internal product development, and operational excellence [2] Future Outlook - Olivier Loeillot expressed enthusiasm for leading Repligen, highlighting the company's culture of innovation and commitment to excellence [7] - The Board is confident that Loeillot will build on the strong foundation established by Hunt and lead the company through its next growth phase [1][3]

WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the following June investor conferences. A live webcast of the conference presentations will be accessible through Repligen's Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a ...

Sondra S. Newman Global Head of Investor Relations (781) 419-1881 investors@repligen.com William Blair's 44th Annual Growth Stock Conference being held in Chicago from June 4 – 6, 2024. Tony J. Hunt, Chief Executive Officer, is scheduled to present a company overview on June 5 at 12:00 p.m. CT. Jefferies' Global Healthcare Conference being held in New York from June 5 – 6, 2024. Olivier Loeillot, President and Chief Commercial Officer and Jason K. Garland, Chief Financial Officer, are scheduled to participa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in its Charter) For the transition period from ___________ to___________ Commission File Number 000-14656 REPLIGEN CORPORATION Delaware 04-2729386 (State or Other Ju ...

Repligen Corporation (NASDAQ:RGEN) Q1 2024 Results Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Sondra Newman - Head of Investor Relations Anthony Hunt - Chief Executive Officer Jason Garland - Chief Financial Officer Olivier Loeillot - President and Chief Commercial Officer Conference Call Participants Rachel Vatnsdal - J.P. Morgan Jacob Johnson - Stephens Inc. Puneet Souda - Leerink Partners Dan Arias - Stifel Conor McNamara - RBC Capital Markets Matt Larew - William Blair & Compan ...